Cipla Forms Joint Venture Company With Chinese Firm For Biosimilars Foray
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - India's top generic drug maker, Cipla, is speeding up its entry into biosimilars with the newly named Biomab, an equal stake joint venture with an undisclosed Chinese company